Global Leading Market Research Publisher QYResearch announces the release of its latest report “Influenza A&B Rapid Test Kits – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Influenza A&B Rapid Test Kits market, including market size, share, demand, industry development status, and forecasts for the next few years.
The Influenza A&B Rapid Test Kits market represents a core segment within the global in-vitro diagnostics (IVD) and point-of-care testing industry, playing a vital role in early respiratory infection screening, outbreak containment, and decentralized clinical decision-making. As global healthcare systems increasingly prioritize rapid, accessible, and scalable diagnostic solutions, influenza rapid testing has become a critical tool across hospitals, clinics, public health agencies, and home-care environments.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6115587/influenza-a-b-rapid-test-kits
From a market valuation perspective, the global Influenza A&B Rapid Test Kits market was estimated to be worth approximately US$ 1,226 million in 2025 and is projected to reach US$ 1,699 million by 2032, growing at a CAGR of 4.8% during the forecast period 2026–2032. This stable growth trajectory is primarily driven by recurring seasonal influenza outbreaks, strengthened global infectious disease surveillance systems, and the long-term structural shift toward decentralized and point-of-care diagnostics.
In terms of product definition, Influenza A&B rapid test kits are in-vitro diagnostic assays designed for the qualitative or semi-quantitative detection of Influenza A and B viral antigens in respiratory specimens. These tests are engineered to deliver fast results—typically within minutes to 30 minutes—enabling timely clinical intervention and infection control measures. Common technological formats include colloidal gold-based lateral flow immunochromatographic assays and fluorescent immunoassay platforms, with the latter increasingly adopted in clinical environments requiring higher sensitivity and digital data integration.
The industry is built upon a complex and highly specialized biomedical supply chain. Upstream components include monoclonal and polyclonal antibodies with high antigen affinity, antigen controls, labeling materials such as colloidal gold nanoparticles or fluorescent microspheres, nitrocellulose membranes, absorbent pads, buffering and stabilizing agents, and precision injection-molded plastic housings. In advanced diagnostic formats, small electronic modules such as photodetectors and portable readers are also integrated to enhance accuracy and enable digital reporting.
Midstream manufacturing processes involve assay design, reagent formulation, strip assembly, quality control, and automated production line integration. Manufacturers must ensure strict consistency in sensitivity and specificity across large-scale production batches, while also meeting regulatory requirements such as FDA approvals, CE certification, and other national in-vitro diagnostic standards. The increasing importance of data connectivity and digital diagnostics is also pushing manufacturers toward integration of software-enabled diagnostic platforms.
Downstream demand is widely distributed across hospital laboratories, primary care clinics, public health and disease control institutions, third-party diagnostic laboratories, pharmacies, institutional screening programs (including schools and enterprises), and home-use consumers. Hospitals and public health agencies generally prefer high-sensitivity fluorescent or instrument-assisted kits for epidemiological monitoring and data aggregation, while retail and primary-care markets continue to rely heavily on cost-effective colloidal gold lateral flow tests due to their simplicity and affordability.
In 2024, global production capacity for Influenza A&B rapid test kits reached approximately 350 million tests, while global shipments were around 280 million tests. The average selling price stood at approximately USD 4.2 per test, and the industry maintained a strong gross margin range of 60%–70%, reflecting the high value-added nature of immunodiagnostic reagents and the recurring demand driven by seasonal influenza cycles.
From a competitive landscape perspective, the market is moderately consolidated, with both multinational diagnostics leaders and fast-growing regional manufacturers competing across different segments of the value chain. Key players include BD, Abbott, Quidel, Actim, Denka, Roche, Thermo Fisher Scientific, Meridian Bioscience, Sekisui Diagnostics, Princeton BioMeditech, Access Bio, Response Biomedical, Guangzhou Wondfo Biotech, Jiangsu Bioperfectus Technologies, Hangzhou Biotest Biotech, Wantai BioPharm, Daan Gene, Kehua Bio-Engineering, and Zhuhai Encode Medical Engineering.
Global leaders such as Abbott, Roche, Thermo Fisher Scientific, and BD maintain strong market positions through extensive R&D capabilities, global regulatory approvals, and diversified diagnostic portfolios spanning molecular, immunoassay, and point-of-care testing platforms. These companies are actively investing in next-generation diagnostic ecosystems that integrate rapid testing with digital health platforms and real-time epidemiological data analytics. Meanwhile, regional players, particularly in Asia, have rapidly expanded their global footprint by leveraging scalable manufacturing capacity, competitive pricing strategies, and accelerating international certification processes.
In terms of segmentation, the market is divided into immunochromatography, colloidal gold method, and other advanced detection technologies. Immunochromatography remains the dominant technology due to its simplicity, rapid turnaround time, and cost efficiency, making it ideal for mass screening applications. However, fluorescent and digitally enhanced assays are gaining traction in hospital and public health settings due to their higher sensitivity and ability to support data-driven clinical workflows.
By application, hospitals represent the largest end-user segment, followed by clinics, home testing, and other institutional uses. The hospital segment continues to anchor demand due to its role in patient triage and infection control. Meanwhile, home testing is emerging as a high-growth segment, driven by increasing consumer health awareness, convenience preferences, and post-pandemic shifts toward self-monitoring of infectious diseases.
The industry is currently undergoing several structural transformations. First, diagnostic decentralization is accelerating, shifting testing from centralized laboratories toward point-of-care and home-based environments. Second, digitalization is enhancing the role of rapid tests within broader healthcare ecosystems, enabling better data integration and outbreak tracking. Third, innovation in assay sensitivity and multiplexing is expanding the clinical utility of rapid influenza diagnostics beyond traditional seasonal screening.
Looking forward, the Influenza A&B Rapid Test Kits market is expected to maintain steady growth, supported by recurring epidemiological demand, increasing global healthcare preparedness, and continuous technological innovation in point-of-care diagnostics. Companies that successfully integrate high-performance biochemical detection with digital diagnostic platforms are expected to strengthen their competitive positioning in the evolving global healthcare landscape.
Overall, the industry remains a strategically essential segment within global infectious disease diagnostics, combining high-volume recurring demand with strong public health relevance and continuous innovation potential.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
